Falchook, G., Rasco, D., Papadopoulos, K., Parikh, A., Mahipal, A., Messersmith, W., Manji, G., Fu, S., Sherman, E., Fein, D., Krop, J., Korth, C., Wang, J., Sharma, M., Spigel, D., Filipovic, A., & Wainberg, Z. (2023). 128P A phase I dose escalation and expansion trial of LYT-200: A galectin-9 antibody +/- tislelizumab. Immuno-Oncology and Technology, 20, 100600. https://doi.org/10.1016/j.iotech.2023.100600